Curis(NASDAQ) CRIS

Curis develops medicines for people with cancer.

Its main drugs aim to help patients with blood cancers and cancers involving the immune system.

These treatments target specific disease pathways to improve patient outcomes.

Products and Services

• Emavusertib (CA-4948): Oral drug for blood cancers like lymphoma and leukemia.
• CI-8993: Antibody treatment designed to help the immune system fight cancer.
• Fimepinostat: Oral drug for certain aggressive lymphomas with genetic changes.
• CA-170: Oral drug targeting immune checkpoints, aiming to help the body attack tumors.
• CA-327: Early-stage cancer drug focused on immune system pathways.

Growth and Expansion

• Formed partnership with Genentech and Roche for Erivedge commercialization (prior to 2025).
• Sold Erivedge royalty rights in Q4 2025, ending product revenue from this source.
• Ongoing collaboration with Aurigene Discovery Technologies for new cancer drug discovery.
• Launched new clinical studies for emavusertib in 2025, expanding its use in blood cancers.

What Makes Curis Stand Out

Curis focuses on precision cancer drugs that target specific disease pathways. The company uses partnerships to share risk and access new technologies. Its pipeline includes both small molecule drugs and antibody treatments for rare cancers.

Five Things You Need to Know

• Revenue was $1 million in Q4 2025, down 66% year-over-year.
• Operating expenses rose to $5 million in Q4 2025, up 53.2% from 2024.
• Net loss improved to $8 million in Q4 2025, a 15.8% year-over-year improvement.
• Cash used in operations was $6 million in Q4 2025, improving 39.9% from 2024.

Bottom Line

Curis has shifted from earning royalties to focusing on developing new cancer drugs. The company faces funding challenges but continues to advance its pipeline through partnerships and clinical trials.